Literature DB >> 18707723

Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer.

Hannes Steiner1, Florian Zangerl, Brigitte Stöhr, Thomas Granig, Henry Ho, Georg Bartsch, Reinhard Peschel.   

Abstract

PURPOSE: We evaluated the feasibility and early oncological outcome of a laparoscopic nerve sparing bilateral retroperitoneal lymph node dissection. The surgical technique is described.
MATERIALS AND METHODS: From July 2004 to December 2007 a total of 42 patients with nonseminomatous germ cell tumor (21 with stage I, 2 with stage IIA marker negative and 19 with post-chemotherapy stage IIB disease) underwent transperitoneal bilateral laparoscopic retroperitoneal lymph node dissection. The sympathetic trunk and postganglionic nerves were identified, and lymphatic tissue was dissected between the nerves. Patients with clinical stage I and IIA disease that was lymph node positive at laparoscopic retroperitoneal lymph node dissection did not receive additional chemotherapy.
RESULTS: Surgery was successfully completed in all patients and no conversion to open surgery was necessary. Mean operative time was 323 minutes. No intraoperative complications occurred. Of patients with stage I and marker negative stage IIA disease active tumor was found in 5 retroperitoneal lymph node dissection specimens, and no patients had recurrence. Of 19 patients with post-chemotherapy stage IIB disease teratoma was found in the lymphatic tissue in 4 (21.0%). No retroperitoneal recurrence was observed. Pulmonary metastases developed 9 months after surgery in 1 patient with stage I disease and negative retroperitoneal histology, and were treated successfully. All patients are currently free of disease at a mean followup of 17.2 months. Antegrade ejaculation was preserved in 36 patients (85.7%).
CONCLUSIONS: Bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection is feasible and associated with low morbidity if performed by experienced hands. The oncological efficacy of this approach is promising and currently under evaluation.

Entities:  

Mesh:

Year:  2008        PMID: 18707723     DOI: 10.1016/j.juro.2008.06.040

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  [Retroperitoneal lymphadenectomy - pro laparoscopy].

Authors:  L Lusuardi; G Janetschek
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

2.  Extraperitoneal laparoscopic retroperitoneal lymph node dissection after chemotherapy for nonseminomatous testicular germ-cell tumor: surgical and oncological outcomes.

Authors:  Yoichi Arai; Yasuhiro Kaiho; Shigeyuki Yamada; Hideo Saito; Koji Mitsuzuka; Shinichi Yamashita; Shunichi Namiki; Haruo Nakagawa; Shigeto Ishidoya; Akihiro Ito
Journal:  Int Urol Nephrol       Date:  2012-05-22       Impact factor: 2.370

3.  [Natural orifice transluminal endoscopic surgery in urology: feasability of a transrectal, flexible retroperitoneoscopy in a porcine model].

Authors:  T Bschleipfer; A Hackethal; S Tacke; P Collet
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

Review 4.  Retroperitoneal lymph node dissection: an update in testicular malignancies.

Authors:  K Yadav
Journal:  Clin Transl Oncol       Date:  2017-02-01       Impact factor: 3.405

Review 5.  Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Authors:  Stephen B Riggs; Earl F Burgess; Kris E Gaston; Caroline A Merwarth; Derek Raghavan
Journal:  Oncologist       Date:  2014-04-09

Review 6.  Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes.

Authors:  Heather J Chalfin; Wesley Ludwig; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

7.  Contemporary lymph node counts during primary retroperitoneal lymph node dissection.

Authors:  R Houston Thompson; Brett S Carver; George J Bosl; Dean Bajorin; Robert Motzer; Darren R Feldman; Victor E Reuter; Joel Sheinfeld
Journal:  Urology       Date:  2010-12-15       Impact factor: 2.649

8.  Management options for stage 1 nonseminomatous germ cell tumors of the testis.

Authors:  Stephen D W Beck
Journal:  Indian J Urol       Date:  2010 Jan-Mar

9.  Risk factors for relapse in patients with clinical stage I testicular nonseminomatous germ cell tumors.

Authors:  Pei Dong; Zhuo-Wei Liu; Xiang-Dong Li; Yong-Hong Li; Kai Yao; Song Wu; Zi-Ke Qin; Hui Han; Fang-Jian Zhou
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

10.  Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.

Authors:  Terukazu Nakamura; Akihiro Kawauchi; Masakatsu Oishi; Takashi Ueda; Takumi Shiraishi; Hiroyuki Nakanishi; Kazumi Kamoi; Yoshio Naya; Fumiya Hongo; Koji Okihara; Tsuneharu Miki
Journal:  Int J Clin Oncol       Date:  2015-12-23       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.